Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
Niclosamide inhibited the NF-kappaB pathway and increased ROS levels to induce apoptosis in AML cells and these results support further investigation of niclosamide in clinical trials of AML patients. Expand
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.
It is found that expression of Aur-A was markedly elevated in bone marrow mononuclear cells obtained from a significant portion of de novo acute myeloid leukemia (AML) patients, and VX-680 enhanced the cytotoxic effect of the chemotherapeutic agent etoposide (VP16) on AML cells. Expand
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
- Zhongzheng Lu, Y. Jin, Chun Chen, Juan Li, Q. Cao, J. Pan
- Biology, Medicine
- Molecular Cancer
- 19 May 2010
This is the first report to show that pristimerin is effective in vitro and in vivo against CML cells, including those with the T315I mutation, indicating that NF-κB inactivation and Bcr-Abl inhibition may be parallel independent pathways. Expand
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
- Yanli Jin, Jingfeng Zhou, +8 authors Jingxuan Pan
- The Journal of clinical investigation
- 3 October 2016
It is suggested that epigenetic methylation modification on histone protein arginine residues is a regulatory mechanism to control self-renewal of L SCs and indicates that PRMT5 may represent a potential therapeutic target against LSCs. Expand
Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin
The findings improve the understanding of LSC regulation and validate Gas6/AXL as a pair of therapeutic targets to eliminate CML LSCs. Expand
Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China
IFI was more common in MDS, AHL, AML, or induction chemotherapy, and substantially increased mortality, and Antifungal prophylaxis showed an independent protective effect but was not commonly used, even in high-risk patients. Expand
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
Analysis of survival in 160 patients demonstrated that loss of ABL-BCR expression, in contrast to deletion status, was not an indicator of poor prognosis, and data support a model in which deletions of the derivative chromosome 9 result in rapid disease progression as a result of the loss of one or more genes within the deleted region. Expand
Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients
It is suggested that MCD is a distinct entity from UCD with a significantly worse outcome, and older age (≥40 years), splenomegaly, and hypoalbuminemia were risk factors for poorer MCD prognosis. Expand
Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study
A pre-chemo risk score was developed that deleted all unpredictable factors before chemotherapy was established, and it confirmed that anti-fungal prophylaxis was beneficial in patients with intermediate and high risk of IFD. Expand
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
A pilot study of treatment with oral arsenic realgar-Indigo naturalis formula (RIF) plus ATRA without chemotherapy, which has a more convenient route of administration than the standard intravenous regimen, showed high efficacy, and non-inferiority was confirmed in the per-protocol population. Expand